To further assess the pharmacokinetic/pharmacodynamic characteristics of methoxy polyethylene glycol‐epoetin β (continuous erythropoiesis receptor activator; C.E.R.A.) in children with chronic kidney disease (CKD) aged 3 months to 18 years undergoing different dialysis… Click to show full abstract
To further assess the pharmacokinetic/pharmacodynamic characteristics of methoxy polyethylene glycol‐epoetin β (continuous erythropoiesis receptor activator; C.E.R.A.) in children with chronic kidney disease (CKD) aged 3 months to 18 years undergoing different dialysis modalities and receiving intravenous/subcutaneous doses, compared with adults.
Keywords:
erythropoiesis receptor;
continuous erythropoiesis;
receptor activator;
activator children;
pharmacokinetic pharmacodynamic
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!